Background The duration of untreated illness (DUI) is a measure to express the latency to first psychopharmacological treatment: It differs among psychiatric disorders, being influenced by several illness-intrinsic and environmental factors. The present study aimed to assess differences in DUI and related variables in patients with schizophrenia (SKZ) versus other schizophrenic spectrum disorders (SSDs) across different epochs. Methods 101 SKZ or SSD patients were assessed with respect to DUI and related variables through clinical interview and questionnaire. Results Patients with SKZ showed earlier ages of onset, first diagnosis and first antipsychotic treatment compared with patients with other SSDs (F = 11.02, p < 0.001; F = 12.68, p < 0.001; F = 13.74, p < 0.001, respectively) who showed an earlier access to benzodiazepines than SKZ patients (F = 6.547; p < 0.05). Dividing the total sample by the epoch of onset (before 1978; between 1978-2000; after 2000) showed a significantly later age of onset in patients with onset within the two most recent epochs (F = 7.46; p < 0.001) and a reduced DUI across epochs (from 144 to 41 to 20 months, on average; F = 11.78, p < 0.001). Conclusion Schizophrenic patients showed earlier onset and longer DUI compared with patients with other SSDs. Data on the total sample showed a later age of onset and a reduced DUI across epochs.

Access and latency to first antipsychotic treatment in Italian patients with schizophrenia and other schizophrenic spectrum disorders across different epochs / M. Palazzo, C. Arici, B. Dell'Osso, L. Cremaschi, B. Grancini, G. Camuri, B. Benatti, L. Oldani, C. Dobrea, A. Cattaneo, A.C. Altamura. - In: HUMAN PSYCHOPHARMACOLOGY. - ISSN 0885-6222. - 31:2(2016 Mar), pp. 113-120. [10.1002/hup.2518]

Access and latency to first antipsychotic treatment in Italian patients with schizophrenia and other schizophrenic spectrum disorders across different epochs

M. Palazzo;C. Arici
Secondo
;
B. Dell'Osso;L. Cremaschi;G. Camuri;B. Benatti;L. Oldani;C. Dobrea;A.C. Altamura
Ultimo
2016

Abstract

Background The duration of untreated illness (DUI) is a measure to express the latency to first psychopharmacological treatment: It differs among psychiatric disorders, being influenced by several illness-intrinsic and environmental factors. The present study aimed to assess differences in DUI and related variables in patients with schizophrenia (SKZ) versus other schizophrenic spectrum disorders (SSDs) across different epochs. Methods 101 SKZ or SSD patients were assessed with respect to DUI and related variables through clinical interview and questionnaire. Results Patients with SKZ showed earlier ages of onset, first diagnosis and first antipsychotic treatment compared with patients with other SSDs (F = 11.02, p < 0.001; F = 12.68, p < 0.001; F = 13.74, p < 0.001, respectively) who showed an earlier access to benzodiazepines than SKZ patients (F = 6.547; p < 0.05). Dividing the total sample by the epoch of onset (before 1978; between 1978-2000; after 2000) showed a significantly later age of onset in patients with onset within the two most recent epochs (F = 7.46; p < 0.001) and a reduced DUI across epochs (from 144 to 41 to 20 months, on average; F = 11.78, p < 0.001). Conclusion Schizophrenic patients showed earlier onset and longer DUI compared with patients with other SSDs. Data on the total sample showed a later age of onset and a reduced DUI across epochs.
No
English
duration of untreated illness (DUI); epochs of onset; schizophrenia (SKZ); schizophrenic spectrum disorders (SSDs); neurology (clinical); psychiatry and mental health; neurology; pharmacology (medical)
Settore MED/25 - Psichiatria
Articolo
Esperti anonimi
Pubblicazione scientifica
mar-2016
Wiley
31
2
113
120
8
Pubblicato
Periodico con rilevanza internazionale
scopus
Aderisco
info:eu-repo/semantics/article
Access and latency to first antipsychotic treatment in Italian patients with schizophrenia and other schizophrenic spectrum disorders across different epochs / M. Palazzo, C. Arici, B. Dell'Osso, L. Cremaschi, B. Grancini, G. Camuri, B. Benatti, L. Oldani, C. Dobrea, A. Cattaneo, A.C. Altamura. - In: HUMAN PSYCHOPHARMACOLOGY. - ISSN 0885-6222. - 31:2(2016 Mar), pp. 113-120. [10.1002/hup.2518]
reserved
Prodotti della ricerca::01 - Articolo su periodico
11
262
Article (author)
no
M. Palazzo, C. Arici, B. Dell'Osso, L. Cremaschi, B. Grancini, G. Camuri, B. Benatti, L. Oldani, C. Dobrea, A. Cattaneo, A.C. Altamura
File in questo prodotto:
File Dimensione Formato  
palazzo et al, 2016.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 291.4 kB
Formato Adobe PDF
291.4 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/437260
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact